The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIV.b

Sulfhemoglobinemia

Publications

Moritz BW, Chouairi F, Tosh A, Toffaletti JG, Rackley CR

A 36-Year-Old Woman With Intermittent Cyanosis.

Chest. 2024;166(2):e29-e33

Soderstrom M, Foster DV, Hamidi ZS, Anderson JT

Sulfhemoglobinemia in a 53-Year-Old With a History of Phenazopyridine Misuse.

Cureus. 2023;15(6):e40944

Kermani TA, Pislaru SV, Osborn TG

Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2009;15(3):127-9

Gopalachar AS, Bowie VL, Bharadwaj P

Phenazopyridine-induced sulfhemoglobinemia.

The Annals of pharmacotherapy. 2005;39(6):1128-30

Halvorsen SM, Dull WL

Phenazopyridine-induced sulfhemoglobinemia: inadvertent rechallenge.

The American journal of medicine. 1991;91(3):315-7